EUVIMEDEUVIMED entdecken
Crossref

Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis

Shohei Fukunaga, Masahiro Egawa, Manabu Shiono, Takafumi Ito, Kazuaki Tanabe

Clinical Nephrology · 2023

DOI: 10.5414/cn111012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nephrology, 2023. Verfasst von Shohei Fukunaga und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Chronic Kidney Disease-Mineral and Bone Disorder.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic Kidney Disease-Mineral and Bone DisorderMaleFemaleHumansMiddle AgedAgedRenal DialysisCalciumParathyroid HormonePhosphorus

Substanzen

CalciumParathyroid HormonePhosphorus

Zitieren

APA

Fukunaga, S., Egawa, M., Shiono, M., Ito, T., & Tanabe, K. (2023). Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis. Clinical Nephrology. https://doi.org/10.5414/cn111012

Vancouver

Fukunaga S, Egawa M, Shiono M, Ito T, Tanabe K. Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis. Clinical Nephrology. 2023. doi:10.5414/cn111012

BibTeX
@article{Fukunaga2023,
  author = {Fukunaga, Shohei and Egawa, Masahiro and Shiono, Manabu and Ito, Takafumi and Tanabe, Kazuaki},
  title = {Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis},
  journal = {Clinical Nephrology},
  year = {2023},
  doi = {10.5414/cn111012}
}
Kostenlos starten →